TLP
NBIX icon

Tri Locum Partners’s Neurocrine Biosciences NBIX Stock Holding History

Tri Locum Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-196,390
Closed -$20.9M – 87
2022
Q3 		$20.9M Buy
+196,390
New +$19.9M 5.73% 4
2021
Q1 		– Sell
-7,178
Closed -$688K – 66
2020
Q4 		$688K Buy
+7,178
New +$693K 0.25% 38

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tri Locum Partners's NBIX Position: Q4 2022 in Review

Tri Locum Partners sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 196,390 shares — an estimated $20.9M sold.

Tri Locum Partners first reported a position in NBIX in Q4 2020 and held it in 2 quarters. The position peaked at $20.9M in Q3 2022. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

  • Tri Locum Partners reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
  • Tri Locum Partners sold 196,390 Neurocrine Biosciences shares in Q4 2022, an estimated $20.9M.
  • Tri Locum Partners first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 2 quarters.
  • Tri Locum Partners's Neurocrine Biosciences position peaked at $20.9M in Q3 2022.
  • 529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Tri Locum Partners's 13F filing for Q4 2022, filed 14 Feb 2023.